YU55998A - Oral or implant pharmaceutical formulation with controlled release - Google Patents

Oral or implant pharmaceutical formulation with controlled release

Info

Publication number
YU55998A
YU55998A YU55998A YU55998A YU55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A
Authority
YU
Yugoslavia
Prior art keywords
oral
controlled release
pharmaceutical formulation
implant
implant pharmaceutical
Prior art date
Application number
YU55998A
Other languages
Serbo-Croatian (sh)
Serbian (sr)
Inventor
C Nay John Leeper
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU55998A publication Critical patent/YU55998A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj pronalazak izlaže postupak za lečenje kongestivnog poremećaja srca i sastoji se od uzimanja delotvorne količine 4-hloro-5- (imidazolin-2-ilamino)-6-metoksi-2-metilpirimidina u oralnoj ili implatnoj formulaciji sa odloženim otpuštanjem i formulacijama sa odloženim otpuštanjem.The present invention provides a method of treating congestive heart failure and comprises taking an effective amount of 4-chloro-5- (imidazolin-2-ylamino) -6-methoxy-2-methylpyrimidine in an oral or delayed release implant formulation and a delayed release formulation .

YU55998A 1996-06-06 1998-12-04 Oral or implant pharmaceutical formulation with controlled release YU55998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
YU55998A true YU55998A (en) 1999-11-22

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
YU55998A YU55998A (en) 1996-06-06 1998-12-04 Oral or implant pharmaceutical formulation with controlled release

Country Status (17)

Country Link
EP (1) EP0914128A1 (en)
JP (1) JP2000511906A (en)
KR (1) KR20000016406A (en)
CN (1) CN1226166A (en)
AU (1) AU3233197A (en)
BR (1) BR9709546A (en)
CA (1) CA2256720A1 (en)
CZ (1) CZ397698A3 (en)
EA (1) EA199900006A1 (en)
HU (1) HUP0003885A2 (en)
IL (1) IL126966A0 (en)
NO (1) NO985695L (en)
PL (1) PL330637A1 (en)
TR (1) TR199802496T2 (en)
WO (1) WO1997046241A1 (en)
YU (1) YU55998A (en)
ZA (1) ZA974978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (en) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
CA2361600C (en) * 1999-02-01 2008-08-26 Solvay Pharmaceuticals Gmbh Use of moxonidine for postmyocardial infarction treatment
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (en) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 Shade for a traffic signal lamp having reflective layer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (en) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermal drug
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
DE4325491A1 (en) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4423177A1 (en) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglycemic drugs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
NO985695D0 (en) 1998-12-04
AU3233197A (en) 1998-01-05
WO1997046241A1 (en) 1997-12-11
HUP0003885A2 (en) 2001-04-28
EP0914128A1 (en) 1999-05-12
CN1226166A (en) 1999-08-18
CA2256720A1 (en) 1997-12-11
IL126966A0 (en) 1999-09-22
KR20000016406A (en) 2000-03-25
NO985695L (en) 1999-02-04
PL330637A1 (en) 1999-05-24
CZ397698A3 (en) 1999-05-12
BR9709546A (en) 1999-08-10
TR199802496T2 (en) 1999-02-22
EA199900006A1 (en) 1999-06-24
JP2000511906A (en) 2000-09-12
ZA974978B (en) 1998-12-07

Similar Documents

Publication Publication Date Title
SE9901973D0 (en) Implants for bone application and procedure and use in such implants
DK0671957T3 (en) Method of Treating a Metal Surgical Implant
DE3877174D1 (en) REFERENCE SYSTEM FOR THE IMPLANTATION OF CONDYLAIR KNEE TOTAL PROSTHESES.
DE69526937D1 (en) USE OF METHANBISPHOSPHONIC ACID DERIVATIVES FOR TREATING LOSSED PROSTHESES
TR199802441A3 (en) Method and composition for the treatment and prevention of the presence of excess uric acid in the blood.
ZA984463B (en) Fused dihydropyrans
ITBO920452A0 (en) "METHOD FOR THE CREATION OF IMPLANT PROSTHESES AND DEVICE FOR THE IMPLEMENTATION OF THIS METHOD".
MX9704037A (en) 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
DE69814394D1 (en) USE OF LEVOBUPIVACAIN
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
DE3852389D1 (en) Prevention of crack formation in implanted prostheses.
YU55998A (en) Oral or implant pharmaceutical formulation with controlled release
DE69626816D1 (en) USE OF SELEGILIN FOR THE TREATMENT OF HEARING LOSS IN MAMMALS
TR199801988T2 (en) Method for the treatment of heart failure with endothelin antagonists.
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
ITBO970245A0 (en) DEVICE AND ANCHORING METHOD FOR THE IMPLANTATION OF BIFURCATED STENTS.
DE69734349D1 (en) TREATMENT OF BONE DRESS WITH ADRENOMEDULLIN
MX9704035A (en) Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
MX9704036A (en) 2-(2,3,5,6-tetrafluoro-4-pyridyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
NO984198D0 (en) Method of treating aggression
EE04951B1 (en) Use of R - (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol for the treatment of sleep disorders
ITRM940240A0 (en) ENDOSSEOUS IMPLANT AND FINISHING SOCKET FOR PROSTHETIC ABUTMENT.
KR900007413A (en) Prevention of AIDS, treatment and composition for the treatment
IT1279984B1 (en) ARMOR FOR THE IMPLANTATION OF DENTAL IMPLANT PROSTHESIS, REMOVABLE, IN PARTICULAR TEMPORARY
MX9605327A (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration.